Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NAT1 | P18440 | 6/20 | 0.74 |
| ▸ | CISD1 | Q9NZ45 | 5/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.63 |
| ▸ | MYC | P01106 | 1/20 | 0.61 |
| ▸ | MAX | P61244 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8310306 | 1.00 | MEN1 (1.00) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL20006065 | 0.89 | NPC1 (0.80) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL8535412 | 0.88 | PTGS2 (0.85) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL17464816 | 0.88 | CISD1 (0.85) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL8535410 | 0.88 | PTGS2 (0.85) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL18102959 | 0.85 | MEN1 (0.73) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL29532726 | 0.84 | MEN1 (0.73) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL8172622 | 0.84 | MEN1 (0.73) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL8172626 | 0.84 | MEN1 (0.73) | MEN1NPC1ALDH1A1LMNAPOLB | |
| SCHEMBL17397854 | 0.84 | MYC (0.77) | MEN1NPC1ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | claimed |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | PARIS SCIENCES ET LETTRES (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES (FR) | 2022-06-02 | — | — | US | disclosed |
| EP-3947355-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres (FR) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201538-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) | 2020-10-08 | — | — | WO | disclosed |
| EP-3719007-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-10-07 | — | — | EP | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5731336-A | USING ARYL-SUBSTITUTED RHODAMINES | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| WO-1996022772-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| US-5464856-A | Arylmethylenyl derivatives of imidazolidinones useful as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| CN-1091006-A | Chemical compound as blood sugar lowering and treatment degenerative brain disorder | LILLY CO ELI (US) | 1994-08-24 | — | — | CN | disclosed |
| US-5306822-A | Mono-, di- or tri-methoxyphenylmethylene-2-thioxo-4-oxazolidinone as antihistamines | WARNER-LAMBERT COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5208250-A | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0343643-A2 | Arylmethylenyl derivatives of thiazolidnones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflamatory agents | WARNER-LAMBERT COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | BLVRB, IK, HBG2 | MEN1 3845/4885NPC1 4836/4885ALDH1A1 4678/4885 |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | BLVRB, HBG2, Q6ZSR9 | MEN1 3100/4885NPC1 4614/4885ALDH1A1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.